Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:FBIO NASDAQ:IDYA NASDAQ:MNPR NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$6.18-3.3%$7.34$5.85▼$24.17$181.62M2.37476,192 shs707,674 shsFBIOFortress Biotech$3.42-7.8%$2.84$1.77▼$4.53$113.61M1.21718,063 shs762,691 shsIDYAIDEAYA Biosciences$35.93-2.2%$32.11$21.33▼$40.58$3.16B-0.091.14 million shs822,856 shsMNPRMonopar Therapeutics$108.52-0.2%$74.77$29.18▼$112.57$726.98M1.46210,568 shs193,675 shsOVIDOvid Therapeutics$2.45-1.6%$2.51$0.41▼$3.11$457.27M0.182.63 million shs1.52 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.31%-12.47%-12.82%-27.71%-51.41%FBIOFortress Biotech-0.54%+23.67%+29.72%+57.87%+91.24%IDYAIDEAYA Biosciences+0.25%-3.21%+21.53%+13.01%+71.44%MNPRMonopar Therapeutics+8.92%+9.49%+76.82%+88.37%+173.37%OVIDOvid Therapeutics+1.22%-8.79%+10.18%-11.07%+576.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$6.18-3.3%$7.34$5.85▼$24.17$181.62M2.37476,192 shs707,674 shsFBIOFortress Biotech$3.42-7.8%$2.84$1.77▼$4.53$113.61M1.21718,063 shs762,691 shsIDYAIDEAYA Biosciences$35.93-2.2%$32.11$21.33▼$40.58$3.16B-0.091.14 million shs822,856 shsMNPRMonopar Therapeutics$108.52-0.2%$74.77$29.18▼$112.57$726.98M1.46210,568 shs193,675 shsOVIDOvid Therapeutics$2.45-1.6%$2.51$0.41▼$3.11$457.27M0.182.63 million shs1.52 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.31%-12.47%-12.82%-27.71%-51.41%FBIOFortress Biotech-0.54%+23.67%+29.72%+57.87%+91.24%IDYAIDEAYA Biosciences+0.25%-3.21%+21.53%+13.01%+71.44%MNPRMonopar Therapeutics+8.92%+9.49%+76.82%+88.37%+173.37%OVIDOvid Therapeutics+1.22%-8.79%+10.18%-11.07%+576.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 2.64Moderate Buy$24.25292.39% UpsideFBIOFortress Biotech 2.25Hold$17.00397.08% UpsideIDYAIDEAYA Biosciences 2.82Moderate Buy$50.2539.86% UpsideMNPRMonopar Therapeutics 3.07Buy$108.750.21% UpsideOVIDOvid Therapeutics 2.89Moderate Buy$5.13109.18% UpsideCurrent Analyst Ratings BreakdownLatest OVID, IDYA, FBIO, MNPR, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026MNPRMonopar Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/13/2026MNPRMonopar Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2026FBIOFortress Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)7/7/2026IDYAIDEAYA Biosciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$53.00 ➝ $48.007/7/2026IDYAIDEAYA Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $63.006/30/2026MNPRMonopar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$104.00 ➝ $117.006/29/2026MNPRMonopar Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/29/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.006/12/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.006/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$42.35M4.15N/AN/A$7.53 per share0.82FBIOFortress Biotech$63.26M1.80N/AN/A$2.00 per share1.71IDYAIDEAYA Biosciences$218.71M14.43N/AN/A$11.67 per share3.08MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/AOVIDOvid Therapeutics$7.25M63.07N/AN/A$1.00 per share2.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$65.78M-$2.81N/AN/AN/A-143.80%-36.55%-28.40%8/10/2026 (Estimated)FBIOFortress Biotech$6.82M$3.171.08N/AN/A193.12%109.66%45.56%8/13/2026 (Estimated)IDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/4/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)OVIDOvid Therapeutics-$17.41M-$0.29N/AN/AN/A-240.11%-22.51%-18.67%8/12/2026 (Estimated)Latest OVID, IDYA, FBIO, MNPR, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026FBIOFortress Biotech-$0.20N/AN/AN/A$18.30 millionN/A8/12/2026Q2 2026OVIDOvid Therapeutics-$0.10N/AN/AN/A$0.04 millionN/A8/11/2026Q2 2026MNPRMonopar Therapeutics-$0.67N/AN/AN/AN/AN/A8/10/2026Q2 2026ARCTArcturus Therapeutics-$0.9964N/AN/AN/A$3.11 millionN/A8/4/2026Q2 2026IDYAIDEAYA Biosciences-$1.0572N/AN/AN/A$7.98 millionN/A5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/12/2026Q1 2026OVIDOvid Therapeutics-$0.12-$0.12N/A-$0.12$0.06 millionN/A5/8/2026Q1 2026ARCTArcturus Therapeutics-$1.0320-$0.95+$0.0820-$0.95$6.30 million$2.06 million5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.7111.57%N/AN/A N/AFBIOFortress BiotechN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A6.316.31FBIOFortress Biotech0.182.862.77IDYAIDEAYA BiosciencesN/A10.7410.74MNPRMonopar TherapeuticsN/A56.0456.04OVIDOvid Therapeutics0.0610.1710.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%FBIOFortress Biotech96.51%IDYAIDEAYA Biosciences98.29%MNPRMonopar Therapeutics1.83%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics17.80%FBIOFortress Biotech28.50%IDYAIDEAYA Biosciences4.70%MNPRMonopar Therapeutics9.70%OVIDOvid Therapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableFBIOFortress Biotech17033.22 million23.75 millionOptionableIDYAIDEAYA Biosciences8087.86 million83.73 millionOptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableOVIDOvid Therapeutics60186.64 million173.58 millionOptionableOVID, IDYA, FBIO, MNPR, and ARCT HeadlinesRecent News About These CompaniesOvid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business OfficerJuly 14 at 7:11 AM | insidermonkey.comOvid Therapeutics Boosts Capital Through Warrant ExercisesJuly 9, 2026 | theglobeandmail.comOvid Therapeutics Promotes Charles Carter to Chief Financial Officer in Leadership ShuffleJuly 8, 2026 | marketwatch.comOvid Therapeutics appoints Charles Carter as new CFOJuly 8, 2026 | tipranks.comOvid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of DevelopmentJuly 8, 2026 | globenewswire.comOvid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% RallyJuly 7, 2026 | seekingalpha.comOvid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS ExpansionsJuly 7, 2026 | seekingalpha.comOvid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS ExpansionsJuly 7, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)June 9, 2026 | theglobeandmail.comOvid Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2026 | globenewswire.comOvid Therapeutics Expands Board, Appoints New Scientific DirectorJune 3, 2026 | tipranks.comOvid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of DirectorsJune 3, 2026 | globenewswire.comOvid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price TargetMay 26, 2026 | tipranks.comFormer Ovid CEO Dr. Jeremy Levin’s rallying cry for biotechMay 15, 2026 | finance.yahoo.comWe're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash WiselyMay 14, 2026 | finance.yahoo.comOvid Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comHere is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny StocksMay 9, 2026 | insidermonkey.com5 Best Fast Growing Penny Stocks to Buy Right NowMay 8, 2026 | insidermonkey.comOvid Therapeutics Inc.April 20, 2026 | edition.cnn.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Ovid Therapeutics (OVID) and Legend Biotech (LEGN)April 17, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesOracle’s Sell-Off Looks More Like a Mispricing Than a WarningBy Thomas Hughes | June 23, 20263 Inflation-Fighting Stocks Built for Higher Oil PricesBy Thomas Hughes | June 21, 2026Credo Technologies Accelerates AI—Its Stock Price Will FollowBy Thomas Hughes | June 18, 2026Rocket Lab's NASA Win Tests Key Support After Sharp PullbackBy Ryan Hasson | June 26, 2026Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponBy Jeffrey Neal Johnson | July 2, 2026OVID, IDYA, FBIO, MNPR, and ARCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$6.18 -0.21 (-3.29%) Closing price 04:00 PM EasternExtended Trading$6.18 +0.00 (+0.08%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Fortress Biotech NASDAQ:FBIO$3.42 -0.29 (-7.82%) Closing price 04:00 PM EasternExtended Trading$3.50 +0.08 (+2.46%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.IDEAYA Biosciences NASDAQ:IDYA$35.93 -0.81 (-2.20%) Closing price 04:00 PM EasternExtended Trading$36.26 +0.33 (+0.90%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Monopar Therapeutics NASDAQ:MNPR$108.52 -0.17 (-0.16%) Closing price 04:00 PM EasternExtended Trading$113.38 +4.87 (+4.48%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Ovid Therapeutics NASDAQ:OVID$2.45 -0.04 (-1.61%) Closing price 04:00 PM EasternExtended Trading$2.46 +0.00 (+0.20%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
